Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus prednisone versus placebo plus prednisone in progressive metastatic hormone-refractory prostate cancer after docetaxel failure
2008-002158-40Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Sunitinib plus prednisone with Placebo plus prednisone (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started May 2008; status: terminated.
02
Drugs
sunitinibprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2008-002158-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002158-40.